Blueprint Medicines

CAMBRIDGE, MA · Biotech · Acquired

Precision therapy platform identifying and targeting genomic driver mutations in cancer and rare genetic diseases

Claim this profile

Follows are private to you and power your alerts

Updated · blueprintmedicines.com

Sector
Biotech
Headquarters
CAMBRIDGE, MA
Latest Form D
$50M, Nov 2014
Total capital
$73.2M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$73.2M
2 Form D · last Nov 2014
143 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
19
21 pending · first 2024
Rank in peer group#4 of 342

Capital timeline

2014FEDERAL ↑EQUITY ↓Cumulative $73.2M1st Form D$23.2M2nd Form D$50M
2014FEDERAL ↑EQUITY ↓Cumulative $73.2M1st Form D$23.2M2nd Form D$50M

Latest events

  • Private capital raisedForm D · SEC · 2nd filing$50M
  • Private capital raisedForm D · SEC · 1st filing$23.2M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

1 record has no date or no amount, so it isn’t placed on the timeline.

Standing among 342 peers

Line = median

Biotech · Platform

  • Granted patents#4 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Alexis BorisyExecutive Officer, DirectorNamed in SEC Form D filings
  • Christine W. BellonExecutive OfficerNamed in SEC Form D filings
  • Christoph S. LengauerExecutive OfficerNamed in SEC Form D filings
  • Daniel S. LynchDirectorNamed in SEC Form D filings
  • David S. SchenkeinDirectorNamed in SEC Form D filings
  • Jeffrey W. AlbersExecutive Officer, DirectorNamed in SEC Form D filings
Show all 11 people
  • Kyle KuvalankaExecutive OfficerNamed in SEC Form D filings
  • Nicholas S. LydonDirectorNamed in SEC Form D filings
  • Nick S. LydonDirectorNamed in SEC Form D filings
  • Stephen S. KnightDirectorNamed in SEC Form D filings
  • Thilo S. SchroederDirectorNamed in SEC Form D filings

What it has protected

USPTO · 19 granted of 40
Show all 40 patent records
  • Comanche BiopharmaSimilar federal contract value in Biotech · null in contracts
  • Expansion TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • SepternaSimilar federal contract value in Biotech · null in contracts
  • Spark Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • Kate TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • Phosplatin Therapeutics Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .